Armando L. Morera-Fumero

Armando L. Morera-Fumero


Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AMArmando L. Morera-Fumero
Armando L. Morera-Fumero
PAPedro Abreu-Gonzalez
Pedro Abreu-Gonzalez
Schizophrenia is a chronic mental disease that disturbs several cognitive functions, such as memory, thought, perception and volition. Schizophrenia’s biological etiology is multifactorial and is still under investigation. Melatonin has been involved in schizophrenia since the first decades of the twentieth century. Research into melatonin regarding schizophrenia has followed two different approaches. The first approach is related to the use of melatonin as a biological marker. The second approach deals with the clinical applications of melatonin as a drug treatment. In this paper, both aspects of melatonin application are reviewed. Its clinical use in schizophrenia is emphasized.

25 February 2013 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Closed access
PDF file
SCSilvia Yelmo Cruz
Silvia Yelmo Cruz
AMArmando L. Morera-Fumero
Armando L. Morera-Fumero
ALArmando L.
Armando L.
PAPedro Abreu‐González
Pedro Abreu‐González

14 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LLLeonardo Lorente
Leonardo Lorente
MMMaría M Martín
María M Martín
PAPedro Abreu-González
Pedro Abreu-González
ADAlberto Domínguez-Rodríguez
Alberto Domínguez-Rodríguez
LLLorenzo Labarta
Lorenzo Labarta
AMArmando L. Morera-Fumero
Armando L. Morera-Fumero
The oxidant/antioxidant state in septic patients has only been studied in small series. We wished to determine whether malondialdehyde (MDA) serum levels were associated with severity and 30-day mortality in a large series of patients with sepsis. We performed an observational, prospective, multicenter study in six Spanish Intensive Care Units. Serum levels of MDA were measured in a total of 228 patients (145 survivors and 83 non-survivors) with severe sepsis and 100 healthy controls. Serum levels of MDA were higher in severe septic patients than in healthy controls. Non-surviving septic patients had higher MDA values than survivors. MDA serum levels were associated with severity markers (lactic acid, SOFA, APACHE-II) and coagulation indices. Regression analysis showed that MDA serum levels were associated with 30-day survival (Hazard ratio = 1.05; 95% confidence interval = 1.009–1.091; p = 0.016). Receiver operating characteristic analysis showed that the area under curve of MDA serum levels to predict 30-day survival was 0.62 (95% CI = 0.56–0.69; P = 0.002). The risk of death in septic patients with MDA serum levels above 4.11 nmol/mL was higher than in patients with lower values (Hazard Ratio = 2.43; 95% CI = 1.49–3.94; p<0.001). The novel findings of our study on severe septic patients, to our knowledge the largest series providing data on the oxidative state, are that elevated MDA serum levels probably represent an unbalanced oxidant state and are related with poor prognosis in patients with severe sepsis.

25 July 2006 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
AMArmando L. Morera-Fumero
Armando L. Morera-Fumero
PAP. Abreu
P. Abreu

1 April 1999 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Closed access
PDF file
AMArmando L. Morera-Fumero
Armando L. Morera-Fumero
PBP. Barreiro
P. Barreiro
JCJ. L. Cano‐Mufioz
J. L. Cano‐Mufioz

1 March 2017 in Psychiatry Research
Verified
Journal Article
Closed access
AMArmando L. Morera-Fumero
Armando L. Morera-Fumero
EDEstefanía Díaz-Mesa
Estefanía Díaz-Mesa
PAPedro Abreu-Gonzalez
Pedro Abreu-Gonzalez
LFLourdes Fernandez-Lopez
Lourdes Fernandez-Lopez
MCMaria del Rosario Cejas-Mendez
Maria del Rosario Cejas-Mendez